Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. 2004

Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. ganesan.v@duke.edu

BACKGROUND A fluorine substituted derivative of meta-iodobenzylguanidine (MIBG), 4-fluoro-3-iodobenzylguanidine (FIBG), is retained in SK-N-SH human neuroblastoma cells in vitro to a higher degree than the MIBG. METHODS To investigate whether the higher retention of FIBG is due to differences in the catabolic degradation of the two tracers, in vitro paired-label studies were performed using SK-N-SH cells. RESULTS No detectable amount of benzyl amines, benzoic acids or hippuran derivatives, potential catabolites of these tracers, were seen in either case. Even after 48 h, the cell culture supernatants contained exclusively intact I-MIBG and I-FIBG. In contrast, in some cases, HPLC analysis of cell lysates indicated the presence of a very polar compound(s) as the predominant species with smaller quantities of intact tracers. The per cent total radioactivity in the lysate at each time point that was associated with intact I-FIBG was (average [range]) 25.4% [20.3-30.5], 22.5% [19.3-25.6], and 18.8% [14.3-23.3], at 0 h, 24 h and 48 h, respectively. The corresponding values for I-MIBG were 24.3% [21.0-27.5], 19.1% [11.7-26.5] and 17.4% [14.6-20.1]. No significant amount of activity was associated with high molecular weight species for either halobenzylguanidine, indicating that protein binding was not a major factor.

UI MeSH Term Description Entries
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019275 Radiopharmaceuticals Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) Radiopharmaceutical
D019797 3-Iodobenzylguanidine A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase. (3-Iodo-(131I)benzyl)guanidine,Iobenguane,MIBG,3-Iodobenzylguanidine, 123I Labeled,3-Iodobenzylguanidine, 125I Labeled,Iobenguane (131I),m-Iodobenzylguanidine,meta-Iodobenzylguanidine,123I Labeled 3-Iodobenzylguanidine,125I Labeled 3-Iodobenzylguanidine,3 Iodobenzylguanidine,3 Iodobenzylguanidine, 123I Labeled,3 Iodobenzylguanidine, 125I Labeled,m Iodobenzylguanidine,meta Iodobenzylguanidine

Related Publications

Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
June 1989, Cancer research,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
August 2000, International journal of cancer,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
January 1997, Oncology reports,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
December 1985, Cancer research,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
June 1988, Cancer research,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
May 2005, Toxicology letters,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
June 2017, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
July 1999, Biological & pharmaceutical bulletin,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
August 2007, Journal of pineal research,
Ganesan Vaidyanathan, and Donna J Affleck, and Kevin L Alston, and Philip Welsh, and Michael R Zalutsky
January 1991, International journal of cancer,
Copied contents to your clipboard!